Market Research Industry Reports

Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company, which discovers and develops medicines to people suffering with difficult-to-treat diseases. It focuses on small molecule drugs designed to address diseases in the areas of cancer and inflammation. The companys product pipeline comprises lead product candidate, duvelisib, also known as IPI-145 is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase 3. The product is being evaluated in various product development stages for the treatment of indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL) and advanced hematologic malignancies. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Partnerships 11
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
Licensing Agreements 14
PellePharm Enters into Licensing Agreement with Infinity Pharma 14
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 15
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 17
Equity Offering 18
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 18
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 19
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 21
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 22
Infinity Pharmaceuticals Inc - Key Competitors 24
Infinity Pharmaceuticals Inc - Key Employees 25
Infinity Pharmaceuticals Inc - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Nov 07, 2017: Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results 27
Aug 03, 2017: Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results 29
May 09, 2017: Infinity Provides Company Reports First Quarter 2017 Financial Results 32
Mar 14, 2017: Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results 33
Corporate Communications 35
Mar 08, 2018: Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board 35
Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer 37
Jan 04, 2017: Infinity Announces Organizational Changes 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List Of Tables

List of Tables
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 10
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 11
Pharm-Olam International Enters into Agreement with Infinity Pharma 12
Lead Discovery Center Partners with Infinity Pharma 13
PellePharm Enters into Licensing Agreement with Infinity Pharma 14
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 15
FAAH Pharma Enters into Licensing Agreement with Infinity Pharma 17
Infinity Pharmaceuticals to Raise USD50 Million in Offering of Common Stock 18
Infinity Pharma Completes Public Offering Of Common Stock For US$173 Million 19
Infinity Pharma Completes Private Placement Of Shares For US$78.5 Million 21
Infinity Pharma Completes Public Offering Of Common Stock For US$88 Million 22
Infinity Pharmaceuticals Inc, Key Competitors 24
Infinity Pharmaceuticals Inc, Key Employees 25
Infinity Pharmaceuticals Inc, Subsidiaries 26

List Of Figures

List of Figures
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Infinity Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Infinity Pharmaceuticals Inc (INFI) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Infinity Pharmaceuticals Inc (Infinity Pharmaceuticals) is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of cancer. The companys pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to

USD 250View Report

Infinity Turbine LLC Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Infinity Turbine LLC Company Profile is a detailed strategic and analytical report on Infinity Turbine LLC. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Urigen Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Urigen Pharmaceuticals Inc (Urigen) is a specialty pharmaceutical company that develops and commercializes therapeutic products for urological disorders. The company focuses on developing innovative products for amelioration of urethritis, painful

USD 250View Report

Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The companys six US FDA-approved medicines and product

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :40
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube